Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: A randomized prospective clinical trial

Citation
M. Moore et al., Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: A randomized prospective clinical trial, J AM COLL S, 192(5), 2001, pp. 591-599
Citations number
36
Categorie Soggetti
Surgery,"Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
ISSN journal
10727515 → ACNP
Volume
192
Issue
5
Year of publication
2001
Pages
591 - 599
Database
ISI
SICI code
1072-7515(200105)192:5<591:FSRTDA>2.0.ZU;2-0
Abstract
BACKGROUND: Patients who have axillary dissections during lumpectomy or modified radica l mastectomy for breast carcinoma accumulate serosanguinous fluid, potentia lly resulting in a seroma. Currently accepted practice includes insertion o f one or more drains for fluid evacuation. This multicenter, randomized, co ntrolled, phase II study was undertaken to evaluate whether a virally inact ivated, investigational fibrin sealant is safe and effective when used as a sealing agent to reduce the duration and volume of serosanguinous fluid dr ainage and to determine the dose response: of this effect. STUDY DESIGN: Patients undergoing lumpectomy or modified radical mastectomy were randomiz ed to treatment with 4, 8, or 16mL of fibrin sealant or control (no agent) at the axillary dissections site. Patients undergoing modified radical mast ectomy also received an additional 4 or 8 mt of fibrin sealant at the skin flap site. Efficacy was evaluated by the number of days required for wound drainage and the volume of fluid drainage compared with control. Safety was confirmed by clinical course, the absence of viral seroconversion, and no major complications attributable co the sealant. RESULTS: The 4-mL axillary dissection dose of fibrin sealant significantly reduced t he duration and quantity of fluid drainage from the axilla following lumpec tomy (p less than or equal to 0.05). In the modified radical mastectomy pat ients, a 16-mL axillary dissection dose combined with an 8-mL skin flap dos e was significantly effective in reducing the number of days to drain remov al (p less than or equal to 0.05) and fluid drainage (p less than or equal to 0.01). There were no fibrin sealant patient viral seroconversions and no major complications attributable to the sealant. A number of wound infecti ons were noted, although this may represent a center-specific effect. CONCLUSIONS: Application of fibrin sealant following axillary dissection at the time of lumpectomy or modified radical mastectomy can significantly decrease the du ration and quantity of serosanguinous drainage. The viral safety of the pro duct was also supported. (J Am Coll Surg 2001;192: 591-599. (C) 2001 by the American College of Surgeons).